Back to Feed
ClinicalTrials.gov|Clinical Trial
Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL
The First Affiliated Hospital of Soochow University
Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, relapse after CAR-T has been a major issue. Multi-antigen CAR T and combination with other regimens may reduce the relapse rate. We conduct pre-auto-HSCT immunotherapy to achieve MRD negative remission, then perform auto-HSCT followed by CD22/CD19 CAR-T "sandwich " strategy in AYA and adult patients with B-ALL. The main Purpose of this study was to observe the safety and efficacy of this new strategy. Phase: PHASE2 Status: NOT_YET_RECRUITING Conditions: Acute Lymphobkastic Leukemia Interventions: Sandwich stratergy
Keywords
Acute Lymphobkastic Leukemia